Sunyoung Jang1, Oluseye Ogunmoroti1, Chiadi E Ndumele1,2,3, Di Zhao1,3, Vishal N Rao4, Oluwaseun E Fashanu5, Martin Tibuakuu1,6, James D Otvos7, Eve-Marie Benson2, Pamela Ouyang2, Erin D Michos1,2,3. 1. Ciccarone Center for the Prevention of Cardiovascular Disease (S.J., O.O., C.E.N., D.Z., M.T., E.D.M.), Johns Hopkins University School of Medicine, Baltimore, MD. 2. Division of Cardiology (C.E.N., E.-M.B., P.O., E.D.M.), Johns Hopkins University School of Medicine, Baltimore, MD. 3. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health (C.E.N., D.Z., E.D.M.). 4. Division of Cardiology Duke University School of Medicine, Durham, NC (V.N.R.). 5. Department of Medicine, Saint Agnes Hospital, Baltimore, MD (O.E.F.). 6. Department of Medicine, St Luke's Hospital, Chesterfield, MO (M.T.). 7. Laboratory Corporation of America Holdings, Morrisville, NC (J.D.O.).
Abstract
BACKGROUND: GlycA, a nuclear magnetic resonance composite marker of systemic inflammation, reflects serum concentration and glycosylation state of main acute phase reactants. Prior studies have shown plasma GlycA levels were associated with cardiovascular disease even after adjusting for other inflammatory markers. However, little is known about the association of GlycA with the heart failure (HF) subtypes: heart failure with preserved ejection fraction (HFpEF) or heart failure with reduced ejection fraction. We examined the association of GlycA with incident HF and its subtypes in a multiethnic cohort. METHODS: We studied 6507 Multi-Ethnic Study of Atherosclerosis participants aged 45 to 84 without baseline cardiovascular disease or HF who had data on GlycA and incident hospitalized HF. We used multivariable-adjusted Cox hazards models to evaluate the association of GlycA with incident total HF, HFpEF, and heart failure with reduced ejection fraction. Models were adjusted for sociodemographics, cardiovascular disease risk factors, and inflammatory biomarkers. RESULTS: The mean (SD) for age was 62 (10) years and for GlycA was 375 (82) μmol/L; 53% women. Over a median follow-up of 14.0 years, participants in the highest quartile of GlycA, compared with the lowest, experienced increased risk of developing any HF (hazard ratio, 1.48 [95% CI, 1.01-2.18]) in fully adjusted models. However, this increased risk was only seen for HFpEF (2.18 [1.15-4.13]) and not heart failure with reduced ejection fraction [1.06 (0.63-1.79)]. There was no significant interaction by sex, age, or race/ethnicity. CONCLUSIONS: GlycA was associated with an increased risk of any HF, and in particular, HFpEF. Future studies should examine mechanisms that might explain differential association of GlycA with HF subtypes, and whether therapeutic lowering of GlycA can prevent HFpEF development. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT00005487.
BACKGROUND:GlycA, a nuclear magnetic resonance composite marker of systemic inflammation, reflects serum concentration and glycosylation state of main acute phase reactants. Prior studies have shown plasma GlycA levels were associated with cardiovascular disease even after adjusting for other inflammatory markers. However, little is known about the association of GlycA with the heart failure (HF) subtypes: heart failure with preserved ejection fraction (HFpEF) or heart failure with reduced ejection fraction. We examined the association of GlycA with incident HF and its subtypes in a multiethnic cohort. METHODS: We studied 6507 Multi-Ethnic Study of Atherosclerosisparticipants aged 45 to 84 without baseline cardiovascular disease or HF who had data on GlycA and incident hospitalized HF. We used multivariable-adjusted Cox hazards models to evaluate the association of GlycA with incident total HF, HFpEF, and heart failure with reduced ejection fraction. Models were adjusted for sociodemographics, cardiovascular disease risk factors, and inflammatory biomarkers. RESULTS: The mean (SD) for age was 62 (10) years and for GlycA was 375 (82) μmol/L; 53% women. Over a median follow-up of 14.0 years, participants in the highest quartile of GlycA, compared with the lowest, experienced increased risk of developing any HF (hazard ratio, 1.48 [95% CI, 1.01-2.18]) in fully adjusted models. However, this increased risk was only seen for HFpEF (2.18 [1.15-4.13]) and not heart failure with reduced ejection fraction [1.06 (0.63-1.79)]. There was no significant interaction by sex, age, or race/ethnicity. CONCLUSIONS:GlycA was associated with an increased risk of any HF, and in particular, HFpEF. Future studies should examine mechanisms that might explain differential association of GlycA with HF subtypes, and whether therapeutic lowering of GlycA can prevent HFpEF development. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT00005487.
Authors: Wendy Ying; Di Zhao; Pamela Ouyang; Vinita Subramanya; Dhananjay Vaidya; Chiadi E Ndumele; Kavita Sharma; Sanjiv J Shah; Susan R Heckbert; Joao A Lima; Christopher R deFilippi; Matthew J Budoff; Wendy S Post; Erin D Michos Journal: J Clin Endocrinol Metab Date: 2018-11-01 Impact factor: 5.958
Authors: Cyrus M Sani; Elahn P L Pogue; Joanna B Hrabia; Alexander G Zayachkowski; Magdaline M Zawadka; Adrian G Poniatowski; Dorota Długosz; Wiktoria Leśniak; Olga Kruszelnicka; Bernadeta Chyrchel; Andrzej Surdacki Journal: Folia Med Cracov Date: 2018
Authors: Sandi L Navarro; Theodore M Brasky; Yvonne Schwarz; Xiaoling Song; C Y Wang; Alan R Kristal; Mario Kratz; Emily White; Johanna W Lampe Journal: Cancer Epidemiol Biomarkers Prev Date: 2012-05-07 Impact factor: 4.254
Authors: Barry M Massie; Peter E Carson; John J McMurray; Michel Komajda; Robert McKelvie; Michael R Zile; Susan Anderson; Mark Donovan; Erik Iverson; Christoph Staiger; Agata Ptaszynska Journal: N Engl J Med Date: 2008-11-11 Impact factor: 91.245
Authors: Michael Fliotsos; Di Zhao; Vishal N Rao; Chiadi E Ndumele; Eliseo Guallar; Gregory L Burke; Dhanajay Vaidya; Joseph Chris A Delaney; Erin D Michos Journal: J Am Heart Assoc Date: 2018-11-20 Impact factor: 5.501
Authors: Wunan Zhou; Meron Teklu; Vy Bui; Grigory A Manyak; Promita Kapoor; Amit K Dey; Alexander V Sorokin; Nidhi Patel; Heather L Teague; Martin P Playford; Julie Erb-Alvarez; Justin A Rodante; Andrew Keel; Sujata M Shanbhag; Li-Yueh Hsu; David A Bluemke; Marcus Y Chen; Marcus Carlsson; Nehal N Mehta Journal: Am J Prev Cardiol Date: 2021-05-30
Authors: Ty Sweeney; Renato Quispe; Thomas Das; Stephen P Juraschek; Seth S Martin; Erin D Michos Journal: Expert Rev Precis Med Drug Dev Date: 2021-05-26
Authors: Richard A Ferraro; Oluseye Ogunmoroti; Di Zhao; Chiadi E Ndumele; Vishal Rao; Ambarish Pandey; Nicholas B Larson; Suzette J Bielinski; Erin D Michos Journal: J Card Fail Date: 2021-05-26 Impact factor: 6.592
Authors: Sunyoung Jang; Oluseye Ogunmoroti; Di Zhao; Oluwaseun E Fashanu; Martin Tibuakuu; Eve-Marie Benson; Faye Norby; James D Otvos; Susan R Heckbert; Moyses Szklo; Erin D Michos Journal: PLoS One Date: 2021-03-25 Impact factor: 3.240
Authors: Angelica Ezeigwe; Oluseye Ogunmoroti; Anum S Minhas; Carla P Rodriguez; Brigitte Kazzi; Oluwaseun E Fashanu; Olatokunbo Osibogun; Lara C Kovell; Colleen M Harrington; Erin D Michos Journal: Front Cardiovasc Med Date: 2022-09-14